A new drug combo for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pucotenlimab, for people with advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread. The goal is to see if this treatment is safe and works well, especially for those with a protein called TROP2 on their cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced bile duct cancer, gallbladder cancer, or intrahepatic/extrahepatic cholangiocarcinoma that cannot be removed or has spread.
- You have not had certain prior treatments like TROP2-targeted therapy or immune checkpoint inhibitors.
- You have not had other cancers in the last 3 years, except for minor skin cancers or cervical cancer in situ.
- You are in good enough health to carry out daily activities (ECOG score 0 or 1) and have adequate organ function.
- You do not have active autoimmune diseases, active hepatitis B or C, or HIV/AIDS.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two immunotherapy drugs—pucotenlimab (a PD-1 inhibitor that boosts your immune system) and becotatugvedotin (an antibody-drug that targets EGFR cancer cells)—can shrink advanced cholangiocarcinoma (bile duct or gallbladder cancer). The goal is to see if this combination works better and is safe for patients whose cancer cannot be surgically removed or has spread.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This trial tests a combination of three medicines—an immunotherapy (sintilimab), an anti-angiogenic drug (bevacizumab), and two chemotherapy drugs (gemcitabine and cisplatin, called AG)—as a first treatment for bile duct cancer that cannot be removed by surgery. The goal is to see if this cocktail can shrink tumors or slow their growth better than standard therapy.
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests a new two-drug combination (sacituzumab tirumotecan and envafolimab) for people with advanced bile duct or gallbladder cancer that has already been treated with immunotherapy plus chemotherapy. It aims to see if these drugs can shrink or control the cancer.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.